| Sex, No. (%) |
| Female |
10 (50) |
| Type of HCT, No. (%) |
| Allogeneic |
10 (50) |
| HCT Conditioning, No. (%) |
| Myeloablative |
14 (70) |
| Underlying Diagnosis, No. (%) |
| Non-Hodgkin Lymphoma |
11 (55) |
| Acute Myeloid Leukemia |
4 (25) |
| Acute Lymphoblastic Leukemia |
4 (20) |
| Other |
1 (5) |
| Cumulative Anthracycline Dose |
| Median, mg/m2 (Range) |
200 (0-420) |
| Age at Assessment, No. (%) |
| ≥65 years old |
10 (50%) |
| Time Since HCT |
| Median, years (Range) |
9.8 (3-20) |
| Karnofsky Score at Assessment |
| Median (Range) |
90 (70-100) |
| Cardiovascular Risk Factors at Assessment, No. (%) |
| Hypertension |
11 (55) |
| Diabetes |
4 (20) |
| Dyslipidemia |
14 (70) |
| Overweight/Obesity (>25 kg/m2) |
7 (35) |
